1st Quarter - Termination

MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY

Firm
Client
Income
—
Expenses
$440,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Apr 4, 2014

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

HR 4302 Protecting Access to Medicare Act of 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4302 (113th)

Budget/Appropriations BUD

H. Con. Res. 96-- Establishing the budget for the U.S. Government for FY 2015 and setting forth appropriate budgetary levels for FY 2016 through 2024 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs.

LobbyistCovered position, as disclosed
AARTI SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.Con.Res. 96 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.